NUVB compared with AARD: revenue, margins and what each company keeps, and the suppliers and customers both name

NUVBNuvation Bio Inc.

Mkt capRevenueRevenue

AARDAardvark Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

NUVBNuvation Bio Inc.

AARDAardvark Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

NUVB

2 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±19.6%▼−4.08%×0.21

May 5 '26±14.9%▲+9.52%×0.64

Q1 FY26±23.9%▼−25.34%×1.06

Jan 12 '26±11.0%▼−19.65%×1.78

AARD

0 of 3at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±54.2%▼−8.62%×0.16

May 7 '26±56.7%▼−4.92%×0.09

= impliedNUVB realized, solidAARD realized, hatchedOne scale, both sides: full bar = 90%× = |realized| ÷ impliedSource: market data

Q1 FY26

±89.9%

▼−7.26%

×0.08

Q3 FY25—▼−8.66%—

NUVBNuvation Bio Inc.

4.71▲+2.66%

Mkt cap$1.6BRevenue$32MQ2 FY26Revenue$63MFY25

AARDAardvark Therapeutics, Inc.

1.25▲+4.17%

Regular sessionNov 3 '26

Mkt cap$29.7MRevenue—Revenue—

Compare

Regular sessionNov 3 '26

NUVBNuvation Bio Inc.

AARDAardvark Therapeutics, Inc.

4.71▲+2.66%

Price

1.25▲+4.17%

$1.6B

Mkt cap

$29.7M

Q2 FY26$32M

Revenue

—

FY25$63M

Revenue

—

NUVB4.71▲+2.66%vsAARD1.25▲+4.17%Regular sessionNov 3 '26